Reports and Briefs on Central Nervous System

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

Type Product title / description Pub Price
Report
Report

The Orphan Drug Market Outlook to 2017

This report provides an analysis of the orphan drug market. It comprises brands that have gained US FDA orphan drug approval, as well as Phase III pipeline candidates that have gained an orphan drug designation from the FDA.

Published By Datamonitor
08 Jan 2013 $3500
Buy
Report
Report

Treatment Algorithms: Postherpetic Neuralgia – Lyrica forms the cornerstone of treatment for postherpetic neuralgia

Analysis of the treatment dynamics in postherpetic neuralgia (PHN). Contains analyses of presentation, diagnosis and treatment rates, and prescribing trends across the seven major markets using Datamonitor’s primary research of 131 physicians.

Published By Datamonitor
13 Nov 2012 $7600
Buy
Report
Report

Market and Product Forecasts: Alzheimer's Disease – Multi-billion dollar potential in high-risk pipeline

Datamonitor uses a patient-based approach to size the commercial potential of Alzheimer’s disease across the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK) from 2011 to 2021.

Published By Datamonitor
25 Oct 2012 $11400
Buy
Report
Report

Product Profiles: Alzheimer's Disease - Amyloid setbacks prolong wait for disease modification

In-depth analysis of key brands and pipeline agents indicated for the treatment of Alzheimer’s disease. Provides a comparative evaluation of clinical and commercial drug attributes to determine competitiveness in the marketplace.

Published By Datamonitor
05 Oct 2012 $11400
Buy
Report
Report

R&D Trends: Chronic Nociceptive Pain – Abundance fails to be matched by innovation

Review of key trends in the chronic nociceptive pain pipeline. Includes a detailed analysis of clinical trial design, target product profile, innovative early-stage approaches and future treatment developments.

Published By Datamonitor
21 Sep 2012 $3800
Buy
Report
Report

Market and Product Forecasts: Top 10 Neurology Brands: 2011–21

Assessment of the current and future top 10 neurology brands using a sales-based forecasting methodology. The analysis is designed to understand the future dynamics of the branded neurology market, with a particular focus on leading therapies.

Published By Datamonitor
20 Sep 2012 $11400
Buy
Report
Report

Central Nervous System Drug Delivery Specialists

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel CNS treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $3800
Buy
Report
Report

Delivery Across the Blood-Brain Barrier

CNS drugs are associated with longer development times and higher attrition rates than drugs for other therapy areas. Advances in delivery technologies are essential if the pursuit of novel treatments is to remain commercially viable.

Published By Datamonitor
05 Sep 2012 $3800
Buy
Report
Report

Drug Discovery for Rare Diseases

Favorable legislation and recent commercial successes have stimulated growing interest in the discovery of novel orphan drugs. However, there are many strategic considerations that are peculiar to the R&D process for diseases of low prevalence.

Published By Datamonitor
31 Aug 2012 $3800
Buy
Report
Report

Prescribing Influences: Bipolar Disorders - Improved control of bipolar depression persists as greatest unmet need

This report analyzes the unmet needs of bipolar disorders treatment and the attributes of drugs that influence the prescribing decisions made by psychiatrists across the seven major markets.

Published By Datamonitor
30 Jul 2012 $3800
Buy

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | » »|

No help is available.